Abstract
Prolactinomas account for approximately 40 % of all pituitary adenomas. Over 95 % of prolactinomas are microadenomas (< 10 mm diameter). Treatment is indicated to correct hypogonadism, restore other hormonal deficits, and alleviate local mass effects. Dopamine agonists (DA) are highly effective in achieving these goals and are well-tolerated. The vast majority of prolactinomas will respond to conventional doses of cabergoline (≤2 mg/week) that do not carry an increased risk of cardiac valvular abnormalities. DA therapy may be successful withdrawn in a subset of patients and thus is not necessarily a lifelong commitment. Although transsphenoidal surgery (TSS) is an option for prolactinoma treatment, it is less effective than medical management, carries considerably more risk, and is more expensive. The benefit/risk ratio for DA therapy compared to TSS actually becomes increasingly more favorable as tumor size increases. Therefore DA should remain the clear treatment of choice for essentially all patients with prolactinomas, reserving TSS as a second-line option for the very small number of patients that do not tolerate or are completely resistant to DA therapy.
Similar content being viewed by others
References
A.F. Daly, M.A. Tichomirowa, A. Beckers, The epidemiology and genetics of pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab. 23(5), 543–554 (2009). doi:10.1016/j.beem.2009.05.008
A. Ciccarelli, A.F. Daly, A. Beckers, The epidemiology of prolactinomas. Pituitary 8(1), 3–6 (2005). doi:10.1007/s11102-005-5079-0
A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72(3), 377–382 (2010). doi:10.1111/j.1365-2265.2009.03667.x
M.P. Gillam, M.E. Molitch, Prolactinoma, in The Pituitary, 3rd edn, ed. by S. Melmed (Elsevier Inc., San Diego, 2011), pp. 475–531
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331(14), 904–909 (1994). doi:10.1056/NEJM199410063311403
V. Pascal-Vigneron, G. Weryha, M. Bosc, J. Leclere, Hyperprolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 24(16), 753–757 (1995)
A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, L. Annunziato, G. Lombardi, Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82(3), 876–883 (1997). doi:10.1210/jcem.82.3.3822
Dekkers OM, Lagro J, Burman P, et al., Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43–51 (2010)
E. Delgrange, T. Daems, J. Verhelst, R. Abs, D. Maiter, Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur. J. Endocrinol. 160(5), 747–752 (2009). doi:10.1530/EJE-09-0012
M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki, O. Kubo, T. Hori, K. Takano, Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93(12), 4721–4727 (2008). doi:10.1210/jc.2007-2758
G. Simonis, J.T. Fuhrmann, R.H. Strasser, Meta-analysis of heart valve abnormalities in parkinson’s disease patients treated with dopamine agonists. Mov. Disord. 22(13), 1936–1942 (2007). doi:10.1002/mds.21639
M.E. Molitch, Management of medically refractory prolactinoma. J. Neurooncol. 117(3), 421–428 (2014). doi:10.1007/s11060-013-1270-8
E. Valassi, A. Klibanski, B.M. Biller, Clinical Review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95(3), 1025–1033 (2010). doi:10.1210/jc.2009-2095
R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, G. Pezzoli, Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc. Ther. 29(6), 404–410 (2011). doi:10.1111/j.1755-5922.2010.00169.x
J. Kharlip, R. Salvatori, G. Yenokyan, G.S. Wand, Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94(7), 2428–2436 (2009). doi:10.1210/jc.2008-2103
A.T. Faje, A. Klibanski, The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: cons. Endocrine (2014). doi:10.1007/s12020-014-0308-9
F.G. Barker 2nd, A. Klibanski, B. Swearingen, Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J. Clin. Endocrinol. Metab. 88(10), 4709–4719 (2003). doi:10.1210/jc.2003-030461
B. Swearingen, Update on pituitary surgery. J. Clin. Endocrinol. Metab. 97(4), 1073–1081 (2012). doi:10.1210/jc.2011-3237
V. Primeau, C. Raftopoulos, D. Maiter, Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. 166(5), 779–786 (2012). doi:10.1530/EJE-11-1000
D.K. Hamilton, M.L. Vance, P.T. Boulos, E.R. Laws, Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8(1), 53–60 (2005). doi:10.1007/s11102-005-5086-1
E.R. Laws Jr, K. Thapar, Pituitary surgery. Endocrinol. Metab. Clin. North. Am. 28(1), 119–131 (1999).
N. Sudhakar, A. Ray, J.A. Vafidis, Complications after trans-sphenoidal surgery: our experience and a review of the literature. Br. J. Neurosurg. 18(5), 507–512 (2004)
P.B. Nelson, M. Goodman, J.C. Maroon, A.J. Martinez, J. Moossy, A.G. Robinson, Factors in predicting outcome from operation in patients with prolactin-secreting pituitary adenomas. Neurosurgery 13(6), 634–641 (1983)
M.E. Molitch, Prolactinoma in pregnancy. Best Pract. Res. Clin. Endocrinol. Metab. 25(6), 885–896 (2011). doi:10.1016/j.beem.2011.05.011
J.E. Tyson, P. Hwang, H. Guyda, H.G. Friesen, Studies of prolactin secretion in human pregnancy. Am. J. Obstet. Gynecol. 113(1), 14–20 (1972)
S. Biswas, C.H. Rodeck, Plasma prolactin levels during pregnancy. Br. J. Obstet. Gynaecol. 83(9), 683–687 (1976)
R. Cohen-Kerem, C. Railton, D. Oren, M. Lishner, G. Koren, Pregnancy outcome following non-obstetric surgical intervention. Am. J. Surg. 190(3), 467–473 (2005). doi:10.1016/j.amjsurg.2005.03.033
N.F. Marko, E. LaSota, A.H. Hamrahian, R.J. Weil, Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J. Neurosurg. 117(3), 522–538 (2012). doi:10.3171/2012.4.JNS11739
C.G. Patil, S.P. Lad, G.R. Harsh, E.R. Laws Jr, M. Boakye, National trends, complications, and outcomes following transsphenoidal surgery for Cushing’s disease from 1993 to 2002. Neurosurg. Focus 23(3), 7 (2007). doi:10.3171/foc.2007.23.3.9
A.S. Little, K. Chapple, H. Jahnke, W.L. White, Comparative inpatient resource utilization for patients undergoing endoscopic or microscopic transsphenoidal surgery for pituitary lesions. J. Neurosurg. (2014). doi:10.3171/2014.2.JNS132095
Conflict of interest
All medications discussed are currently generic. However, MEM has received research support in the past from Novartis and Pfizer for the conduct of studies with bromocriptine and cabergoline.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bloomgarden, E., Molitch, M.E. Surgical treatment of prolactinomas: cons. Endocrine 47, 730–733 (2014). https://doi.org/10.1007/s12020-014-0369-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0369-9